These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 26033180

  • 1. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.
    Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
    [Abstract] [Full Text] [Related]

  • 2. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E.
    Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I.
    Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [Abstract] [Full Text] [Related]

  • 5. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS.
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T.
    BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567
    [Abstract] [Full Text] [Related]

  • 7. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 22; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 8. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R.
    World J Surg Oncol; 2016 Nov 04; 14(1):281. PubMed ID: 27809843
    [Abstract] [Full Text] [Related]

  • 9. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, Asami Y, Inoue T, Yoneda T.
    Ann Oncol; 2015 Oct 04; 26(10):2149-54. PubMed ID: 26205395
    [Abstract] [Full Text] [Related]

  • 10. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM.
    J Bone Joint Surg Am; 2018 Mar 21; 100(6):496-504. PubMed ID: 29557866
    [Abstract] [Full Text] [Related]

  • 11. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
    Abu-Zaid A, Alaqaili SI, Ahmad SO, Bin Hazzaa I, Alharbi H.
    Gulf J Oncolog; 2019 May 21; 1(30):67-75. PubMed ID: 31242985
    [Abstract] [Full Text] [Related]

  • 12. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center.
    Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W.
    J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187
    [Abstract] [Full Text] [Related]

  • 13. Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.
    Bukata SV, Blay JY, Rutkowski P, Skubitz K, Henshaw R, Seeger L, Dai T, Jandial D, Chawla S.
    Spine (Phila Pa 1976); 2021 Mar 01; 46(5):277-284. PubMed ID: 33038190
    [Abstract] [Full Text] [Related]

  • 14. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 01; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 15. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P.
    BMC Cancer; 2021 Jan 22; 21(1):89. PubMed ID: 33482769
    [Abstract] [Full Text] [Related]

  • 16. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.
    Eur J Cancer; 2017 May 22; 76():118-124. PubMed ID: 28324746
    [Abstract] [Full Text] [Related]

  • 17. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S, Hindiskere S, Honoki K, Mavrogenis AF, Tanaka Y, Chinder PS, Donati DM, Errani C.
    Int Orthop; 2023 Jan 22; 47(1):265-273. PubMed ID: 36282294
    [Abstract] [Full Text] [Related]

  • 18. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R.
    Eur J Surg Oncol; 2018 Sep 22; 44(9):1384-1390. PubMed ID: 29650420
    [Abstract] [Full Text] [Related]

  • 19. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
    Duan DK, Zhang GC, Sun BJ, Ma TX, Zhao M.
    Eur Rev Med Pharmacol Sci; 2023 Jun 22; 27(11):5039-5052. PubMed ID: 37318478
    [Abstract] [Full Text] [Related]

  • 20. Denosumab combined with en bloc resection and arthrodesis for recurrent grade 3 giant cell tumor of bone in distal radius.
    Li Z, Deng Z, Yang Y, Gao D, Zhang Q, Niu X, Liu W.
    J Orthop Surg Res; 2024 Sep 28; 19(1):607. PubMed ID: 39342379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.